Current Strategies in Overcoming Resistance of Cancer Cells to Apoptosis Melanoma as a Model

International Review of Cytology

Volumn 251, Issue , 2006, Pages 131-158

  Hersey, Peter ^a   Zhuang, L ^b   Zhang, X D ^a  

^a NEWCASTLE MATER HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Apoptosis; Bcl 2 proteins; Cancer; Signal pathways; Targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; APOPTOSIS INHIBITOR; BIM 46228; BL 193; BORTEZOMIB; CASPASE 2; CURCUMIN; CYTOCHROME C; DACARBAZINE; DNA; GOSSYPOL; GX 015070; IDN 13389; KOS 953; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OBLIMERSEN; PACLITAXEL DERIVATIVE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PX 866; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIPIFARNIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUNICAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER MODEL; CANCER RESISTANCE; CELL DEATH; CELL PROTECTION; CLINICAL TRIAL; DNA DAMAGE; GLIOMA CELL; GLYCOLYSIS; HUMAN; MELANOMA CELL; MITOCHONDRIAL MEMBRANE; MITOSIS INHIBITION; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; REVIEW; SCID MOUSE; SENESCENCE; STRUCTURAL HOMOLOGY; TRANSCRIPTION REGULATION; XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 33747878462     PISSN: 00747696     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7696(06)51004-6     Document Type: Review

References (147)

1. Advani R., Peethambaram P., Lum B.L., Fisher G.A., Hartmann L., Long H.J., Halsey J., Holmlund J.T., Dorr A., and Sikic B.I. A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100 (2004) 321-326
2. Amiri K.I., Horton L.W., LaFleur B.J., Sosman J.A., and Richmond A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 64 (2004) 4912-4918
3. Amiri K.I., and Richmond A. Role of nuclear factor-kB in melanoma. Cancer Meta. Rev. 24 (2005) 301-313
4. An J., Chen Y., and Huang Z. Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor. J. Biol. Chem. 279 (2004) 19133-19140
5. Aplin A.E., Stewart S.A., Assoian R.K., and Juliano R.L. Integrin-mediated adhesion regulates ERK nuclear translocation and phosphorylation of Elk-1. J. Cell Biol. 153 (2001) 273-282
6. Armstrong B. Epidemiology of cutaneous melanoma and current trends. In: Thompson J.F., Morton D.L., and Kroon B.B.R. (Eds). "Textbook of Melanoma" (2004), Martin Dunitz, London 65-80
7. Arnt C.R., Chiorean M.V., Heldebrant M.P., Gores G.J., and Kaufmann S.H. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277 (2002) 44236-44243
8. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2 (2002) 420-430
9. Basu A., Lu D., Sun B., Moor A.N., Akkaraju G.R., and Huang J. Proteolytic activation of protein kinase Cε by caspase-mediated processing and transduction of antiapoptotic signals. J. Biol. Chem. 277 (2002) 41850-41856
10. Bedikian A.Y., Plager C., Stewart J.R., O'Brian C.A., Herdman S.K., Ross M., Papadopoulos N., Eton O., Ellerhorst J., and Smith T. Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res. 11 (2001) 183-188
11. Bellosillo B., Villamor N., Lopez-Guillermo A., Marce S., Bosch F., Campo E., Montserrat E., and Colomer D. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 100 (2002) 1810-1816
12. Bharti A.C., and Aggarwal B.B. Ranking the role of RANK ligand in apoptosis. Apoptosis 9 (2004) 677-690
13. Bogoyevitch M.A., Boehm I., Oakley A., Ketterman A.J., and Barr R.K. Targeting the JNK MAPK cascade for inhibition: Basic science and therapeutic potential. Biochim. Biophys. Acta. 1697 (2004) 89-101
14. Borst P., and Rottenberg S. Cancer cell death by programmed necrosis. Drug Resist. Updates 7 (2004) 321-324
15. L, and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biol. 79 (2000) 355-369
16. Brazil D.P., and Hemmings B.A. Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem. Sci. 26 (2001) 657-664
17. Brichese L., Cazettes G., and Valette A. JNK is associated with Bcl-2 and PP1 in mitochondria: Paclitaxel induces its activation and its association with the phosphorylated form of Bcl-2. Cell Cycle 3 (2004) 1312-1319 (2004)
18. Brown M., and Wilson G. Apoptosis genes and resistance to cancer therapy. Cancer Biol. Ther. 2 (2003) 477-490
19. Burke P.J., McCarthy W.H., and Milton G.W. Imidazole carboxamide therapy in advanced malignant melanoma. Cancer 27 (1971) 744-750
20. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., Colman P.M., Day C.L., Adams J.M., and Huang D.C. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17 (2005) 393-403
21. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., and Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
22. Collins N.L., Reginato M.J., Paulus J.K., Sgroi D.C., Labaer J., and Brugge J.S. G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol. Cell. Biol. 25 (2005) 5282-5291
23. Cory S., and Adams J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2 (2002) 647-656
24. Coultas L., and Strasser A. The molecular control of DNA damage-induced cell death. Apoptosis 5 (2000) 491-507
25. Dai D.L., Martinka M., and Li G. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J. Clin. Oncol. 23 (2005) 1473-1482
26. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W.C., Leung S.Y., Yen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
27. Del Bufalo D., Trisciuoglio D., Scarsella M., Zangemeister-Wittke U., and Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22 (2003) 8441-8447
28. Deng Y., Lin Y., and Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev. 16 (2002) 33-45
29. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., and Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17 (1998) 2215-2223
30. Dokmanovic M., and Marks P.A. Prospects: Histone deacetylase inhibitors. J. Cell. Biochem. 96 (2005) 293-304
31. Dou F., Yuan L.D., and Zhu J.J. Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism. Acta Biochim. Biophys. Sin. 37 (2005) 501-505
32. End D.W., Smets G., Todd A.V., Applegate T.L., Fuery C.J., Angibaud P., Venet M., Sanz G., Poignet H., Skrzat S., Devine A., Wouters W., and Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61 (2001) 131-137
33. Fernandez Y., Verhagen M., Miller T.P., Rush J.L., Steiner P., Opipari Jr. A.W., Lowe S.W., and Soengas M.S. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: Therapeutic implications. Cancer Res. 65 (2005) 6294-6304
34. Flaherty K.S. Phase II trials of BAy 43-9006 alone and in combination with chemotherapy in 'metastatic' melanoma. Abstract 49, 6th World Congress on Melanoma (2005)
35. Fujii T., Garcia-Bermejo M.L., Bernabo J.L., Caamano J., Ohba M., Kuroki T., Li I., Yuspa S.H., and Kazanietz M.G. Involvement of protein kinase Cδ (PKCδ) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCδ. J. Biol. Chem. 275 (2000) 7574-7582
36. Fulda S., Wick W., Weller M., and Debatink K.M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 8 (2002) 808-815
37. Gao Z., Shao Y., and Jiang X. Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. J. Biol. Chem. 280 (2005) 38271-38275
38. Gillespie S., Zhang X.D., and Hersey P. Variable expression of protein kinase Cε in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Mol. Cancer Ther. 4 (2005) 668-676
39. Gomez-Angelats M., and Cidlowski J.A. Protein kinase C regulates FADD recruitment and death-inducing signaling complex formation in Fas/CD95-induced apoptosis. J. Biol. Chem. 276 (2001) 44944-44952
40. Govindarajan B., Bai X., Cohen C., Zhong H., Kilroy S., Louis G., Moses M., and Arbiser J.L. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase (MAPKK) signaling. J. Biol. Chem. 278 (2003) 9790-9795
41. Green D.R., and Evan G.I. A matter of life and death. Cancer Cell 1 (2002) 19-30
42. Guo F., Nimmanapalli R., Paranawithana S., Wittman S., Griffin D., Bali P., O'Bryan E., Fumero C., Wang H.G., and Bhalla K. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99 (2002) 3419-3426
43. Harper N., Hughes M.A., Farrow S.N., Cohen G.M., and MacFarlane M. Protein kinase C modulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by targeting the apical events of death receptor signaling. J. Biol. Chem. 278 (2003) 44338-44347
44. Heere-Ress E., Thallinger C., Lucas T., Schlagbauer-Wadl H., Wacheck V., Monia B.P., Wolff K., Pehamberger H., and Jansen B. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int. J. Cancer 99 (2002) 29-34
45. Herr I., Wilhelm D., Meyer E., Jeremias I., Angel P., and Debatin K.M. JNK/SAPK activity contributes to TRAIL-induced apoptosis. Cell Death Differ. 6 (1999) 130-135
46. Hersey P., and Zhang X.D. How melanoma cells evade TRAIL-induced apoptosis. Nature Reviews 1 (2001) 142-150
47. Hersey P., Zhang X.Y., and Zhang X.D. Regulation of trail receptor expression in human melanoma. In: el-Deiry W.S. (Ed). "Cancer Drug Discovery and Development: Death Receptors in Cancer Therapy" (2005), Humana Press Inc, Totowa, NJ 175-187
48. Houghton J.A. Apoptosis and drug response. Curr. Opin. Oncol. 11 (1999) 475-481
49. Ihle N.T., Williams R., Chow S., Chew W., Berggren M.I., Paine-Murrieta G., Minion D.J., Halter R.J., Wipf P., Abraham R., Kirkpatrick L., and Powis G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3 (2004) 763-772
50. Jansen B., Schlagbauer-Wadl H., Brown B.D., Bryan R.N., van Elsas A., Muller M., Wolff K., Eichler H.G., and Pehamberger H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med. 4 (1998) 232-234
51. Jansen B., Wacheck V., Heere-Ress E., Schlagbauer-Wadl H., Hoeller C., Lucas T., Hoermann M., Hollenstein U., Wolff K., and Pehamberger H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
52. Jin Z., McDonald E.R., Dicker D.T., and el-Deiry W.S. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J. Biol. Chem. 279 (2004) 35829-35839
53. Karl E., Warner K., Zeitlin B., Kaneko T., Wurtzel L., Jin T., Chang J., Wang S., Wang C.Y., Strieter R.M., Nunez G., Polverini P.J., and Nor J.E. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. Cancer Res. 65 (2005) 5063-5069
54. Khayat D., Meric J.-B., and Rixie O. Systemic chemotherapy and biochemotherapy for non-resected and metastatic melanoma. In: Thompson J.F., Morton D.L., and Kroon B.B.R. (Eds). "Textbook of Melanoma" (2004), Martin Dunitz, London 586-601
55. Kirkwood J.M., Bedikian A.Y., Millward M.J., Conry R.M., Gore M.E., Pehamberger H.E., Sterry W., Pavlick A.C., Deconti R.C., and Itri L.M. Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (Oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM). ASCO Meeting Abstract 7506 (2005) 713s
56. Klasa R.J., Gillum A.M., Klem R.E., and Frankel S.R. Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev. 12 (2002) 193-213
57. Lei K., and Davis R.J. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci., USA 100 (2003) 2432-2437
58. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
59. Leu J.I.-J., Dumont P., Hafey M., Murphy M.E., and George D.L. Mitochondrial p53 activates Bak and causes disruption of Bak-Mcl1 complex. Nat. Cell Biol. 6 (2004) 443-450
60. Ley R., Ewings K.E., Hadfield K., Howes E., Balmanno K., and Cook S.J. Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J. Biol. Chem. 279 (2004) 8837-8847
61. Ley R., Ewings K.E., Hadfield K., and Cook S.J. Regulatory phosphorylation of Bim: Sorting out the ERK from the JNK. Cell Death Differ. 12 (2005) 1008-1014
62. Ley R., Hadfield K., Howes E., and Cook S.J. Identification of a DEF-type docking domain for extracellular signal-regulated kinases 1/2 that directs phosphorylation and turnover of the BH3-only protein BimEL. J. Biol. Chem. 280 (2005) 17657-17663
63. Li L., Lorenzo P.S., Bogi K., Blumberg P.M., and Yuspa S.H. Protein kinase targets mitochondria, alters mitochondrial membrane potential, and induces apoptosis in normal and neoplastic keratinocytes when overexpressed by an adenoviral vector Cδ. Mol. Cell. Biol. 19 (1999) 8547-8558
64. Liang X.H., Jackson S., Seaman M., Brown K., Kempkes B., Hibshoosh H., and Levine B. Induction of autophagy and inhibition of tumorigenesis by Beclin 1. Nature 402 (1999) 672-676
65. Lopez-Bergami P., Habelhah H., Bhoumik A., Zhang W., Wang L.H., and Ronai Z. RACK1 mediates activation of JNK by protein kinase C. Mol. Cell 19 (2005) 309-320
66. LoRusso P.M., Adjei A.A., Varterasian M., Gadgeel S., Reid J., Mitchell D.Y., Hanson L., DeLuca P., Bruzek L., Piens J., Asbury P., VanBecelaere K., Herrera R., Sebolt-Leopold J., and Meyer M.B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol. 23 (2005) 5281-5293
67. Lum J.J., Bauer D.E., Kong M., Harris M.H., Li C., Lindsten T., and Thompson C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120 (2005) 237-248
68. Majumder P.K., Pandey P., Sun X., Cheng K., Datta R., Saxena S., Kharbanda S., and Kufe D. Mitochondrial translocation of protein kinase Cδ in phorbol ester-induced cytochrome c release and apoptosis. J. Biol. Chem. 275 (2000) 21793-21796
69. Margolin K., Longmate J., Baratta T., Synold T., Christensen S., Weber J., Gajewski T., Quirt I., and Doroshow J.H. CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Cancer 104 (2005) 1045-1048
70. Martin D.S., Stolfi R.L., and Colofiore J.R. Perspective-The chemotherapeutic relevance of apoptosis and a proposed biochemical cascade for chemotherapeutically induced apoptosis. Cancer Invest. 15 (1997) 372-381
71. Massague J. G1 cell-cycle control and cancer. Nature 432 (2004) 298-306
72. Matassa A.A., Kalkofen R.L., Carpenter L., Biden T.J., and Reyland M.E. Inhibition of PKCα induces a PKCδ-dependent apoptotic program in salivary epithelial cells. Cell Death Differ. 10 (2003) 269-277
73. McGill G.G., Horstmann M., Widlund H.R., Du J., Motyckova G., Nishimura E.K., Lin Y.-L., Ramaswamy S., Avery W., Ding H.-F., Jordan S.A., Jackson I.J., Korsmeyer S.J., Golub T.R., and Fisher D.E. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 109 (2002) 707-718
74. Meng W.H., Heldebrant M.P., and Kaufmann S.H. Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of Fas-associated polypeptide with death domain. J. Biol. Chem. 277 (2002) 3776-3783
75. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., and Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
76. Moll U.M., Wolff S., Speidel D., and Deppert W. Transcription-independent pro-apoptotic function of p53. Curr. Opin. Cell. Biol. 17 (2005) 631-636
77. Molton S.A., Todd D.E., and Cook S.J. Selective activation of the c-Jun-N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3′-kinase (PI3K) pathway is inhibited. Oncogene 22 (2003) 4690-4701
78. Muhlenbeck F., Schneider P., Bodmer J.L., Schwenzer R., Hauser A., Schubert G., Scheurich P., Moosmayer D., Tschopp J., and Wajant H. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J. Biol. Chem. 275 (2000) 32208-32213
79. Munshi A., Kurland J.F., Nishikawa T., Chiao P.J., Andreeff M., and Meyn R.E. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol. Cancer Ther. 3 (2004) 985-992
80. Newton A.C. Protein kinase C: Structure, function, and regulation. J. Biol. Chem. 270 (1995) 28495-28498
81. Nguyen T., Zhang X.D., and Hersey P. Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Clin. Cancer Res. 7 (2001) 966s-973s
82. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258 (1992) 607-614
83. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat. Rev. 4 (2004) 592-603
84. Oliver C.L., Miranda M.B., Shangary S., Land S., Wang S., and Johnson D.E. Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol. Cancer Ther. 4 (2005) 23-31
85. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., and Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
86. Parsons D.W., Wang T.-L., Samuels Y., Bardelli A., Cummins J.M., DeLong L., Silliman N., Ptak J., Szabo S., Willson J.K.V., Markowitz S., Kinzler K.W., Vogelstein B., Lengauer C., and Velculescu V.E. Mutations in a signalling pathway. Nature 436 (2005) 792
87. Pavey S., Johansson P., Packer L., Taylor J., Stark M., Pollock P.M., Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L., Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G., Meltzer P., Ringner M., and Hayward N.K. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23 (2004) 4060-4067
88. Pollock P.M., Walker G.J., Glendening J.M., Que Noy T., Bloch N.C., Fountain J.W., and Hayward N.K. PTEN inactivation is rare in melanoma tumours but occurs frequently in melanoma cell lines. Melanoma Res. 12 (2002) 565-575
89. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., Heenan P., Duray P., Kallioniemi O., Hayward N.K., Trent J.M., and Meltzer P.S. High frequency of BRAF mutations in nevi. Nat. Genet. 33 (2003) 19-20
90. Prevost G.P., Pradines A., Brezak M.C., Lonchampt M.O., Viossat I., Ader I., Toulas C., Kasprzyk P., Gordon T., Favre G., and Morgan B. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. Int. J. Cancer 91 (2001) 718-722
91. Puthalakath H., Villunger A., O'Reilly L.A., Beaumont J.G., Coultas L., Cheney R.E., Huang D.C., and Strasser A. Bmf: A proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293 (2001) 1829-1832
92. Puthalakath H., and Strasser A. Keeping killers on a tight leash: Transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9 (2002) 505-512
93. Qin J.Z., Stennett L., Bacon P., Bodner B., Hendrix M.J., Seftor R.E., Seftor E.A., Margaryan N.V., Pollock P.M., Curtis A., Trent J.M., Bennett F., Miele L., and Nickoloff B.J. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol. Cancer Ther. 3 (2004) 895-902
94. Robertson G.P. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Meta. Rev. 24 (2005) 273-285
95. Romano M.F., Avellino R., Petrella A., Bisogni R., Romano S., and Venuta S. Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur. J. Cancer 40 (2004) 2829-2836
96. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex. Science 307 (2005) 1098-1101
97. Sarker M., Ruiz-Ruiz C., and Lopez-Rivas A. Activation of protein kinase C inhibits TRAIL-induced caspases activation, mitochondrial events and apoptosis in a human leukemic T cell line. Cell Death Differ. 8 (2001) 172-181
98. Sarker M., Ruiz-Ruiz C., Robledo G., and Lopez-Rivas A. Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells. Oncogene 21 (2002) 4323-4327
99. Schimmer A.D. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res. 64 (2004) 7183-7190
100. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., Pedersen I.M., Kitada S., Scott E.L., Bailly-Maitre B., Glinsky G., Scudiero D., Sausville E., Salvesen G., Nefzi A., Ostresh J.M., Houghten R.A., and Reed J.C. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (2004) 25-35
101. Shin S., Lee Y., Kim W., Ko H., Choi H., and Kim K. Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing procaspase-8. EMBO J. 24 (2005) 3532-3542
102. a against TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in glioma cells. Biochem. Biophys. Res. Commun. 284 (2001) 1162-1167
103. Shiraishi T., Yoshida T., Nakata S., Horinaka M., Wakada M., Mizutani Y., Miki T., and Sakai T. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res. 65 (2005) 6364-6370
104. Siwak D.R., Shishodia S., Aggarwal B.B., and Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104 (2005) 879-890
105. Smalley K.S.M. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int. J. Cancer 104 (2003) 527-532
106. Smalley K.S., and Eisen T.G. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int. J. Cancer 105 (2003) 165-175
107. Smith V., Sausville E.A., Camalier R.F., Fiebig H.H., and Burger A.M. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: Effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 56 (2005) 126-137
108. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., and Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (6th November, 2005) 358-362 Advanced online
109. Strumberg D., Richly H., Hilger R.A., Schleucher N., Korfee S., Tewes M., Faghih M., Brendel E., Voliotis D., Haase C.G., Schwartz B., Awada A., Voigtmann R., Scheulen M.E., and Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 23 (2005) 965-972
110. Sutton V.R., Davis J.E., Cancilla M., Johnstone R.W., Ruefli A.A., Sedelies K., Browne K.A., and Trapani J.A. Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J. Exp. Med. 192 (2000) 1403-1413
111. Swannie H.C., and Kaye S.B. Protein kinase C inhibitors. Curr. Oncol. Rep. 4 (2002) 37-46
112. Tang H.J., Jin X., Wang S., Yang D., Cao Y., Chen J., Gossett D.R., and Lin J. A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. Gynecol. Oncol. 100 (Oct 3, 2006) 308-317
113. Thallinger C., Wolschek M.F., Wacheck V., Maierhofer H., Gunsberg P., Polterauer P., Pehamberger H., Monia B.P., Selzer E., Wolff K., and Jansen B. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J. Invest. Dermatol. 120 (2003) 1081-1086
114. Thallinger C., Wolschek M.F., Maierhofer H., Skvara H., Pehamberger H., Monia B.P., Jansen B., Wacheck V., and Selzer E. Mcl-1 is a novel therapeutic target for human sarcoma: Synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin. Cancer Res. 10 (2004) 4185-4191
115. Tinel A., and Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 304 (2004) 843-846
116. Townsend K.J., Zhou P., Qian L., Bieszczad C.K., Lowrey C.H., Yen A., and Craig R.W. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J. Biol. Chem. 274 (1999) 1801-1813
117. Tozer R.G., Burdette-Radoux S., Berlanger K., Davis M.L., Lohmann R.C., Rusthoven J.R., Wainman N., Zee B., Seymour L.,, and and National Cancer Institute of Canada Clinical Trials Group. A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group study. Invest. New Drugs 20 (2002) 407-412
118. Trapani J.A., Sutton V.R., and Smyth M.J. CTL granules: Evolution of vesicles essential for combating virus infections. Immunol. Today 20 (1999) 351-356
119. Trapani J.A., and Sutton V.R. Granzyme B: Pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 15 (2003) 533-543
120. Tsao H., Atkins M.B., and Sober A.J. Management of cutaneous melanoma. N. Engl. J. Med. 351 (2004) 998-1012
121. Tsuruta F., Sunayama J., Mori Y., Hattori S., Shimizu S., Tsujimoto Y., Yoshioka K., Masuyama N., and Gotoh Y. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J. 23 (2004) 1889-1899
122. Vance K.W., Carreira S., Brosch G., and Goding C.R. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanoma. Cancer Res. 65 (2005) 2260-2268
123. Varfolomeev E., Maecker H., Sharp D., Lawrence D., Renz M., Vucic D., and Ashkenazi A. Molecular determinants of kinase pathway activation by apo2 ligand/tumor necrosis factor related apoptosis-inducing ligand. J. Biol. Chem. 280 (Oct 15, 2005) 40599-40609
124. Vaux D.L., and Silke J. IAPs, RINGs and ubiquitylation. Nat. Rev. Mol. Cell. Biol. 6 (2005) 287-297
125. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R., Simpson R.J., and Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102 (2000) 43-53
126. Verhagen A.M., Coulson E.J., and Vaux D.L. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol. 2 (2001) 3009. 1-3009.10
127. Wacheck V., Losert D., Gunsberg P., Vornlocher H.P., Hadwiger P., Geick A., Pehamberger H., Muller M., and Jansen B. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 13 (2003) 393-400
128. Walensky L.D., Kung A.L., Escher I., Malia T.J., Barbuto S., Wright R.D., Wagner G., Verdine G.L., and Korsmeyer S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305 (2004) 1466-1470
129. Wellbrock C., and Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170 (2005) 703-708
130. Whelan R.D., and Parker P.J. Loss of protein kinase C function induces an apoptotic response. Oncogene 16 (1998) 1939-1944
131. Willis S.N., and Adams J.M. Life in the balance: How BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17 (2005) 617-625
132. Woods D., Cherwinski H., Venetsanakos E., Bhat A., Gysin S., Humbert M., Bray P.F., Saylor V.L., and McMahon M. Induction of β3-integrin gene expression by sustained activation of the Ras-regulated Raf-MEK-extracellular signal-regulated kinase signaling pathway. Mol. Cell. Biol. 21 (2001) 3192-3205
133. Wu G., Chai J., Suber T.L., Wu J.-W., Du C., Wang X., and Shi Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 408 (2000) 1008-1012
134. Zamzami N., and Kroemer G. The mitochondrion in apoptosis: How Pandora's box opens. Mol. Cell Biol. 2 (2001) 67-71
135. Zangemeister-Wittke U., Leech S.H., Olie R.A., Simoes-Wust A.P., Gautschi O., Luedke G.H., Natt F., Haner R., Martin P., Hall J., Nalin C.M., and Stahel R.A. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6 (2000) 2547-2555
136. Zeh H.J., and Lotze M.T. Addicted to death: Invasive cancer and the immune response to unscheduled cell death. J. Immunother. 28 (2005) 1-9
137. Zhang L., Yu J., Park B.H., Kinzler K.W., and Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
138. Zhang X.D., Zhang X.Y., Gray C.P., Nguyen T., and Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Res. 61 (2001) 7339-7348
139. Zhang X.D., Borrow J.M., Zhang X.Y., Nguyen T., and Hersey P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 22 (2003) 2869-2881
140. Zhang X.D., Gillespie S.K., Borrow J.M., and Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol. Cancer Ther. 3 (2004) 425-435
141. Zhang X.D., Wu J.J., Gillespie S., Borrow J., and Hersey P. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to TRAIL are more vulnerable to necrotic cell death induced by Cisplatin. Clin. Cancer Res. 12 (2006) 1355-1364
142. Zhang X.Y., Zhang X.D., Borrow J.M., Nguyen T., and Hersey P. Translational control of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor expression in melanoma cells. J. Biol. Chem. 279 (2004) 10606-10614
143. Zheng T.S. Death by design: The big debut of small molecules. Nat. Cell Biol. 3 (2001) E43-E46
144. Zhivotovsky B., and Orrenius S. Caspase-2 function in response to DNA damage. Biochem. Biophys. Res. Commun. 331 (2005) 859-867
145. Zhuang L., Lee C.S., Scolyer R.A., McCarthy S.W., Palmer A.A., Zhang X.D., Thompson J.F., Bron L.P., and Hersey P. Activation of the extracellular-signal related kinase (ERK) pathway in human melanoma. J. Clin. Pathol. 58 (2005) 1163-1169
146. Zhuang L., Lee C.S., Scolyer R.A., McCarthy S.W., Zhang X.D., Thompson J.F., and Hersey P. The anti-apoptotic proteins Mcl-1 and Bcl-XL but not Bcl-2 are associated with progression of melanoma (2006) Submitted
147. Zong W.X., Ditsworth D., Bauer D.E., Wang Z.Q., and Thompson C.B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18 (2004) 1272-1282